S100B and myeloid sarcoma: In their meta-analysis, Momtazmanesh et al. found that the concentration of S100B was significantly higher in the CSF of MS patients compared to controls [17], which is not in line with the lack of differences observed in the concentrations of S100B in the CSF of patients diagnosed de novo with RRMS compared to the controls in [30].